Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from MedAdvisor Limited ( (AU:AHE) ).
Adheris Health Limited has disclosed a change in director’s interests, confirming that Managing Director and CEO John Ciccio has been granted 30 million unlisted options under the company’s 2026 long-term incentive plan. The options, expiring on 30 June 2035, were issued following shareholder approval at an extraordinary general meeting on 12 March 2026, signalling a strong alignment of executive incentives with long-term shareholder value and company performance.
The award of a substantial LTIP package to the chief executive underscores the board’s focus on retention and performance-based remuneration at a time when digital health and medication adherence platforms are under competitive and regulatory pressure. Investors will view the scale and structure of the options as an important indicator of management’s long-term commitment and the company’s expectations for future growth in its healthcare technology markets.
The most recent analyst rating on (AU:AHE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:AHE Stock Forecast page.
More about MedAdvisor Limited
Adheris Health Limited, recently referred to as MedAdvisor Limited, operates in the healthcare technology sector. The company focuses on digital medication management and patient adherence solutions, working with pharmacies, healthcare providers, and pharmaceutical companies to improve health outcomes and engagement.
Average Trading Volume: 490,002
Technical Sentiment Signal: Sell
Current Market Cap: A$12.74M
See more insights into AHE stock on TipRanks’ Stock Analysis page.